I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Cardiac arrest, as a severe critical illness, is still one of the most common causes of disease-related death in children. It has poor neurological outcomes and a low survival rate, approximately 25% for in-hospital arrests and \<10% for out-of-hospital arrests.\[[@ref1]\] An observational study from Hill *et al*.\[[@ref2]\] in 1992 reported early emergency bypass performed in children with cardiac arrest. Since then, an increasing number of studies about extracorporeal cardiopulmonary resuscitation (ECPR) have emerged, showing improved survival rates \>30%, which might be due to the powerful mechanical pulmonary and circulatory support provided by extracorporeal membrane oxygenation (ECMO).\[[@ref3][@ref4][@ref5]\] In 2015, the American Heart Association updated its guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care and recommended that ECPR might be considered in children suffering in-hospital cardiac arrest with cardiac diagnoses.\[[@ref6]\] However, further recommendations and guidelines are absent because of the small number of studies with small sample sizes and narrow diagnoses. Given the rapid expansion of extracorporeal life support (ECLS) worldwide and possible survival benefits in children, more studies in this field are in demand. Moreover, no report has characterized the current situation of ECPR in Asia Pacific. The purposes of this study were to describe the demographic details, diagnosis data, information before and during ECMO support, and clinical outcomes for children with ECPR in Asia Pacific, evaluating their temporal changes and the risk factors associated with in-hospital mortality. This study retrospectively reviewed the data provided by the Extracorporeal Life Support Organization (ELSO) registry and made intensive analyses, focusing on this issue in the Asia Pacific region specifically.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The study was conducted in accordance with the *Declaration of Helsinki* and was approved by the Ethics Committee of Fuwai Hospital and the ELSO Steering Committee.

Data source {#sec2-2}
-----------

ELSO was founded in 1989 and has maintained the world\'s largest registry of ECMO use by collecting data from its active centers. In Asia Pacific, 52 centers from 12 countries and regions contribute data to the registry. After approval by the local Institutional Review Boards, centers gather information using a standardized data form voluntarily. Data use agreements between ELSO and member centers allow for the release of limited de-identified datasets for the purpose of scientific research and publication.

Study population and data categorization {#sec2-3}
----------------------------------------

ECPR, defined by the registry, means using ECLS as a part of initial resuscitation for cardiac arrest. Patients without cardiac arrest would not be considered, though ECMO is used to maintain stable hemodynamics. In this study, the data of ECPR in Asia Pacific from 1999 to 2016 were retrospectively analyzed and divided into two 9-year groups (Group 1: 1999--2007 and Group 2: 2008--2016) to assess temporal changes in demographics and outcomes. Patients should be younger than 18 years of age. Because only single-run details are recorded in the form of ELSO, patients with ECMO run number equal or larger than 2 were excluded from the study. The variables analyzed in this study included demographic data, diagnosis codes (International Classification of Diseases, 9^th^ or 10^th^ Revision, Clinical Modification), pre-ECMO mechanical ventilation information and arterial blood gas values, pre-ECMO support details, ECMO-related information (duration of ventilation before ECMO, hours of ECMO, pump flow at the 4^th^ and 24^th^ h during ECMO, ECMO complications, and others), and clinical outcomes. Two authors independently reviewed the diagnosis, pre-ECLS support, and complication codes. If there was any inconsistency, the corresponding author checked the original data and made a correction. Since some diagnostic groups were small, we defined two categories, named "congenital heart disease" (including all types of congenital anomalies of heart recorded in the registry) and "cerebrovascular disease" (including intracranial hemorrhage, occlusion and stenosis of cerebral arteries, and transient cerebral ischemia). Complications, including mechanical and physiologic ones, were categorized using unified codes determined by the ELSO registry.

Statistical analysis {#sec2-4}
--------------------

The primary outcome measurement was defined as survival to hospital discharge. Demographic data and ECMO-related details were also compared between survivors and nonsurvivors. For categorical variables, data were presented by overall cases (*n*) and proportions (%) and compared with the Chi-square test or Fisher\'s exact test, as appropriate. For continuous variables, normality of distribution was assessed by the Kolmogorov-Smirnov test. The normally distributed data were shown as the mean ± standard deviation, and the abnormally distributed data were shown as median (Q1, Q3). Student\'s *t*-test or the Mann-Whitney *U*-test was used to compare two groups, as appropriate. Multiple logistic regression models were established to explore risk factors associated with hospital death. The inclusion criterion of variables in regression models was a *P* ≤ 0.10 in the bivariate analysis. The first model included demographic and pre-ECLS factors, the second model evaluated ECMO-related factors, and the third model analyzed ECMO complication information. All data were analyzed using SPSS version 23.0 software (IBM, Armonk, New York, USA). The statistical significance was set at a *P* \< 0.05.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Study population {#sec2-5}
----------------

A total of 351 patients younger than 18 years old whose data were contributed to ELSO underwent ECPR from 1999 to 2016 in Asia Pacific. Among them, thirty children whose ECMO run numbers were ≥2 were excluded from later analyses. Finally, 321 children were included in this study. The mean age of the study population was 4.1 (0.7, 58.1) months and 179 (55.8%) were males. Asian patients accounted for 42.7%. The overall survival rate was 50.8% (163/321). The number of ECPR episodes and survival rate per year are presented in [Figure 1](#F1){ref-type="fig"}. Despite the sharp decrease in 2016 (which might be due to delayed reports), an increase in ECPR events could be found from only 1 in 1999 to 48 in 2013. The annual survival rate ranged from 0.0% to 70.4%.

![Annual episodes and survival rates from 1999 to 2016 in this study. ECPR: Extracorporeal cardiopulmonary resuscitation.](CMJ-131-1436-g001){#F1}

Period-based analysis {#sec2-6}
---------------------

[Table 1](#T1){ref-type="table"} shows the temporal changes in demographic and diagnostic variables between Group 1 (1999--2007; *n* = 58) and Group 2 (2008--2016; *n* = 263), as well as information before and during ECMO support. Although the survival rates were similar, the age and weight of children increased over time, accompanied by a smaller proportion of diagnoses of congenital heart disease and cardiogenic shock. Ventilator parameters and arterial blood gas values in the 6 h before ECMO support were worse in Group 2: the respiratory rate, pH, and HCO~3~^−^ values were significantly lower in Group 2 than those in Group 1. Regarding pre-ECLS support, the use of vasopressor/inotropes, and vasodilator drugs dropped over time, while the use of steroids increased. Duration of ventilation before ECMO was significantly shorter in Group 2 than Group 1 (*P* \< 0.001). The rates of ECMO complications showed an overall decrease over time periods, as expected, including oxygenator failure, surgical site hemorrhage, and dialysis use \[[Table 2](#T2){ref-type="table"}\].

###### 

Comparison of demographic and clinical characteristics between two 9-year groups in this study

  Characteristics                              Group 1 (*n* = 58)   Group 2 (*n* = 263)   Statistical values   *P*
  -------------------------------------------- -------------------- --------------------- -------------------- ---------
  Age (months)                                 1.7 (0.3, 19.2)      5.6 (0.8, 64.9)       −2.93\*              0.003
  Weight (kg)                                  3.7 (3.0, 11.5)      6.0 (3.4, 20.3)       −3.14\*              0.002
  Male                                         34 (58.6)            145 (55.1)            0.21^†^              0.649
  Race (Asian)                                 28 (48.3)            109 (41.4)            0.55^†^              0.458
  Survival at hospital discharge               25 (43.1)            138 (52.5)            1.67^†^              0.196
  Diagnosis                                                                                                    
   Sepsis                                      7 (12.1)             13 (4.9)              3.00^†^              0.083
   Arrhythmia                                  2 (3.4)              29 (11.0)             3.13^†^              0.077
   Cerebrovascular disease                     6 (10.3)             10 (3.8)              3.03^†^              0.082
   Acute kidney failure                        11 (19.0)            13 (4.9)              13.51^†^             0.001
   Congenital heart disease                    44 (75.9)            152 (57.8)            6.52^†^              0.011
   Cardiogenic shock                           21 (36.2)            19 (7.2)              36.59^†^             \<0.001
  Pre-ECLS information                                                                                         
   Ventilator parameters                                                                                       
    Respiratory rate (breath/min)              32 (24, 37)          26 (20, 30)           −2.25^‡^             0.025
    FiO~2~ (%)                                 100 (50, 100)        100 (100, 100)        −1.83^‡^             0.068
   Arterial blood gas values                                                                                   
    pH                                         7.3 (7.0, 7.4)       7.1 (7.0, 7.3)        −1.98^‡^             0.048
    HCO~3~^−^ (mmol/L)                         19.2 (13.0, 23.3)    16.0 (12.0, 21.0)     −2.07^‡^             0.039
  Pre-ECLS support                                                                                             
   Vasopressor/inotropes                       55 (94.8)            148 (56.3)            30.38^†^             \<0.001
   Vasodilator drugs                           18 (31.0)            20 (7.6)              24.99^†^             \<0.001
   Bicarbonate                                 34 (58.6)            90 (34.2)             11.93^†^             0.001
   Steroids                                    0 (0.0)              34 (12.9)             8.39^†^              0.004
  ECMO information                                                                                             
   Duration of ventilation before ECMO (h)     18 (7, 59)           3 (1, 22)             −4.78^‡^             \<0.001
   Time of ECMO (h)                            105 (64, 157)        94 (52, 152)          −0.74^‡^             0.459
   Pump flow at 4^th^ h (ml·kg^−1^·min^−1^)    114 (97, 138)        109 (64, 147)         −1.11^‡^             0.268
   Pump flow at 24^th^ h (ml·kg^−1^·min^−1^)   115 (95, 148)        115 (72, 141)         −0.97^‡^             0.334
   FiO~2~ at 24^th^ h (%)                      40 (21, 50)          40 (30, 50)           −1.82^‡^             0.068
   PEEP at 24^th^ h (cmH~2~O)                  8 (4, 10)            10 (6, 10)            −2.91^‡^             0.004
   MAP at 24^th^ h (cmH~2~O)                   11 (9, 12)           12 (10, 13)           −2.67^‡^             0.008

Data are presented as *n* (%) or median (Q1, Q3). \**t* values; ^†^*χ*^2^ values; ^‡^*Z* values. ECLS: Extracorporeal life support; FiO~2~: Fraction of inspired oxygen; ECMO: Extracorporeal membrane oxygenation; PEEP: Positive end-expiratory pressure; MAP: Mean airway pressure; 1 cmH~2~O = 0.098 kPa.

###### 

Comparison of ECMO complications between two 9-year groups in this study

  Items                                  Group 1 (*n* = 58)   Group 2 (*n* = 263)   *χ*^2^   *P*
  -------------------------------------- -------------------- --------------------- -------- ---------
  Mechanical complications                                                                   
   Oxygenator failure                    9 (15.5)             19 (7.2)              4.11     0.043
   Clots in other parts                  18 (31.0)            47 (17.9)             5.10     0.024
  Hemorrhagic complications                                                                  
   Cannulation site                      12 (20.7)            56 (21.3)             0.01     0.919
   Surgical site                         13 (22.4)            28 (10.6)             5.91     0.015
   Hemolysis (PFH \>500 mg/L)            29 (50.0)            38 (14.4)             36.37    \<0.001
   DIC                                   4 (6.9)              9 (3.4)               0.72     0.397
  Neurological complications                                                                 
   Brain death                           4 (6.9)              12 (4.6)              0.17     0.685
   CNS infarction by US/CT               11 (19.0)            17 (6.5)              9.33     0.002
   CNS hemorrhage by US/CT               2 (3.4)              24 (9.1)              1.37     0.243
  Renal complications                                                                        
   Serum creatinine 15--30 mg/L          19 (32.8)            36 (13.7)             12.17    \<0.001
   Dialysis use                          9 (15.5)             8 (3.0)               12.36    \<0.001
   CAVHD use                             6 (10.3)             4 (1.5)               9.51     0.002
  Cardiac complications                                                                      
   Arrhythmia                            2 (3.4)              35 (13.3)             4.53     0.033
   Hypertension requiring vasodilators   9 (15.5)             73 (27.8)             3.74     0.053
  Other complications                                                                        
   Culture proven infection              23 (39.7)            44 (16.7)             15.12    \<0.001
   Blood glucose \<400 mg/L              4 (6.9)              29 (11.0)             0.88     0.349
   Blood glucose \>2400 mg/L             26 (44.8)            67 (25.5)             8.65     0.003
   Blood pH \<7.2 during ECMO            14 (24.1)            38 (14.4)             3.29     0.070
   Blood pH \>7.6 during ECMO            4 (6.9)              25 (9.5)              0.39     0.530

Data are presented as *n* (%). PFH: Plasma free hemoglobin; DIC: Disseminated intravascular coagulation; CNS: Central nervous system; US: Ultrasonography; CT: Computed tomography; CAVHD: Continuous arteriovenous hemodialysis; ECMO: Extracorporeal membrane oxygenation.

Univariate and multiple logistic regression analyses of survival at hospital discharge {#sec2-7}
--------------------------------------------------------------------------------------

Comparisons of demographic features, diagnostic details, and ECMO-related information between survivors and nonsurvivors are provided in [Table 3](#T3){ref-type="table"}. Younger age and lower body weight were associated with survival. There was no significant difference in gender between the two groups (*P* = 0.853), while Asian race was more in nonsurvivors than survivors (*P* \< 0.001). When compared with nonsurvivors, fewer patients suffered from sepsis and cerebrovascular diseases in survivors. Over 60% of survivors received anesthetic and neuromuscular blockers as pre-ECLS support, which was significantly different from nonsurvivors. Respiratory rate and peak inspiratory pressure (PIP) at the 24^th^ h of ECMO support were lower in survivors, compared with nonsurvivors. ECMO complications, including disseminated intravascular coagulation (DIC), myocardial stunning, and neurological complications, were relatively rare in survivors (\<10%). Three multiple logistic regression models of risk factors associated with mortality are shown in [Table 4](#T4){ref-type="table"}. Demographic and pre-ECLS factors (Model I), ECMO-related information (Model II), and ECMO complications (Model III) were evaluated to identify the risk factors associated with in-hospital mortality. Among pre-ECPR variables, Asian race was associated with increased odds of in-hospital mortality, and lower pH value before ECMO support indicated worse outcomes. In the second regression model, higher respiratory rate and PIP at the 24^th^ h were related to lower survival. ECMO complications such as DIC and myocardial stunning confirmed by ultrasound and neurological complications were independently associated with increased odds of in-hospital mortality.

###### 

Comparison of demographic and clinical characteristics between survivors and nonsurvivors in this study

  Items                                        Survivors (*n* = 163)   Nonsurvivors (*n* = 158)   Statistical values   *P*
  -------------------------------------------- ----------------------- -------------------------- -------------------- ---------
  Age (months)                                 2.3 (0.4, 57.2)         7.0 (0.9, 64.0)            −2.19\*              0.029
  Weight (kg)                                  4.6 (3.1, 16.1)         6.2 (3.5, 22.5)            −2.14\*              0.032
  Male                                         92 (56.4)               87 (55.4)                  0.03^†^              0.853
  Race (Asian)                                 54 (34.0)               83 (54.2)                  13.03^†^             \<0.001
  Diagnosis                                                                                                            
   Sepsis                                      5 (3.1)                 15 (9.5)                   5.67^†^              0.017
   Cardiomyopathy                              10 (6.1)                18 (11.4)                  2.79^†^              0.095
   Cerebrovascular disease                     4 (2.5)                 12 (7.6)                   4.48^†^              0.034
   Congenital heart disease                    111 (68.1)              85 (53.8)                  6.90^†^              0.009
  Pre-ECLS information                                                                                                 
   Arterial blood gas values                                                                                           
    pH                                         7.2 (7.0, 7.3)          7.1 (6.9, 7.3)             −1.91^‡^             0.057
    HCO~3~^−^ (mmol/L)                         17.4 (12.7, 22.0)       16.0 (11.8, 21.0)          −1.54^‡^             0.124
  Pre-ECLS support                                                                                                     
   Anesthetic                                  110 (67.5)              76 (48.1)                  12.37^†^             \<0.001
   Neuromuscular blockers                      112 (68.7)              82 (51.9)                  9.49^†^              0.002
   Dobutamine                                  37 (22.7)               21 (13.3)                  4.80^†^              0.029
  ECMO information                                                                                                     
   Duration of ventilation before ECMO (h)     5 (2, 23)               5 (2, 29)                  −0.35^‡^             0.726
   Time of ECMO (h)                            95 (61, 143)            94 (31, 160)               −0.55^‡^             0.583
   Pump flow at 4^th^ h (ml·kg^−1^·min^−1^)    114 (78, 143)           108 (68, 147)              −0.32^‡^             0.746
   Pump flow at 24^th^ h (ml·kg^−1^·min^−1^)   111 (77, 136)           118 (80, 148)              −1.29^‡^             0.198
   Respiratory rate at 24^th^ h (breath/min)   10 (10, 18)             15 (10, 20)                −2.69^‡^             0.007
   PIP at 24^th^ h (cmH~2~O)                   20 (20, 24)             22 (20, 25)                −2.27^‡^             0.023
  ECMO complications                                                                                                   
   Clots in oxygenator                         38 (23.3)               17 (10.8)                  8.91^†^              0.003
   Clots in other parts                        45 (27.6)               20 (12.7)                  11.10^†^             0.001
   DIC                                         3 (1.8)                 10 (6.3)                   4.16^†^              0.041
   Brain death                                 0 (0.0)                 16 (10.1)                  17.37^†^             \<0.001
   CNS infarction by US/CT                     7 (4.3)                 21 (13.3)                  8.16^†^              0.004
   CNS hemorrhage by US/CT                     8 (4.9)                 18 (11.4)                  4.53^†^              0.033
   Vasopressor/Inotropes using during ECLS     78 (47.9)               93 (58.9)                  3.91^†^              0.048
   Myocardial stunning by US                   1 (0.6)                 9 (5.7)                    5.29^†^              0.021
   Hypertension requiring vasodilators         53 (32.5)               29 (18.4)                  8.46^†^              0.004

Data are presented as *n* (%) or median (Q1, Q3). \**t* values; ^†^*χ*^2^ values; ^‡^*Z* values. ECLS: Extracorporeal life support; ECMO: Extracorporeal membrane oxygenation; PIP: Peak inspiratory pressure; DIC: Disseminated intravascular coagulation; CNS: Central nervous system; US: Ultrasonography; CT: Computed tomography; 1 cmH~2~O = 0.098 kPa.

###### 

Multiple regression models of risk factors for in-hospital mortality in children with ECPR

  Factors                                      *OR* (95% *CI*)       *P*
  -------------------------------------------- --------------------- ---------
  Model I. Demographic and pre-ECLS factors                          
   Race (Asian)                                2.98 (1.24--7.12)     0.014
   pH                                          0.27 (0.08--0.88)     0.030
  Model II. ECMO related factors                                     
   Respiratory rate at 24^th^ h (breath/min)   1.05 (1.01--1.09)     0.006
   PIP at 24^th^ h (cmH~2~O)                   1.06 (1.00--1.13)     0.050
  Model III. ECMO complications                                      
   DIC                                         4.51 (1.10--18.48)    0.036
   Neurological complications                  3.41 (1.87--6.23)     \<0.001
   Myocardial stunning by US                   10.23 (1.20--87.41)   0.034

Model I: *n* = 247, Hosmer-Lemeshow test, *P* = 0.569; Model II: *n* = 274, Hosmer-Lemeshow test, *P* = 0.592; Model III: *n* = 321, Hosmer-Lemeshow test, *P* = 0.411. ECLS: Extracorporeal life support; ECMO: Extracorporeal membrane oxygenation; PIP: Peak inspiratory pressure; DIC: Disseminated intravascular coagulation; US: Ultrasonography; ECPR: Extracorporeal cardiopulmonary resuscitation; *OR*: Odds ratio; *CI*: Confidence interval;1 cmH~2~O = 0.098 kPa.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

This study retrospectively analyzed data extracted from the ELSO registry to describe changes in the clinical information of patients younger than 18 years who underwent ECPR in Asia Pacific from 1999 to 2016. A total of 321 patients were included in the study. They had an overall survival rate of 50.8%, which was slightly higher than the result of a previous international study (43%).\[[@ref7]\] This finding might be attributed to regional disparities in economic and medical status, as well as the inclusion criteria for ECPR. With increases in age and weight and decreases in the proportions of diagnoses of congenital heart disease and cardiogenic shock, it seems that the indications for ECPR are expanding. Burke *et al*.\[[@ref8]\] described the use of EPCR in victims of drowning, and Sawamoto *et al*.\[[@ref9]\] showed the survival benefit of ECPR for patients of hypothermia.\[[@ref8][@ref9]\] Despite no apparent advance in survival rate between two groups in this study, the significantly lower pH and HCO~3~^−^ values before ECMO support in Group 2 might indicate that more patients with complex and severe conditions received ECPR in the latter period. These results were similar to the results of a retrospective study involving 1796 adult patients.\[[@ref10]\] Moreover, the decrease in the use of vasoactive drugs might indicate improvements in both technology and experience. It is worth noting that the use of steroids increased over time period. Although there is no consensus about steroid use during CPR, improved survival was not rare among studies worldwide, which could be explained by better hemodynamic stability and less ischemic damage induced by steroids.\[[@ref11]\] Longer deployment times of ECMO during CPR have been associated with poor outcomes.\[[@ref12][@ref13][@ref14][@ref15][@ref16]\] Medical institutions and clinical doctors have devoted themselves to developing new rapid-response systems to enhance the prognosis of those patients, some of which have shown positive effects.\[[@ref17][@ref18][@ref19]\] It is no wonder why we saw a significant decrease in the duration of ventilation time before ECMO from the earlier period to the later one.

In accordance with expectations, the incidence of ECMO complications showed an overall decrease in this study including mechanical, hemorrhagic, neurological, renal, and infection-related complications. In 2010, Palanzo *et al*.\[[@ref20]\] published a brief review about the evolution of ECLS, describing changes in oxygenators, pumps, anticoagulation monitoring, pressure monitoring, the newest circuits, and other factors. The polymethylpentene diffusion membranes, with all the inherent advantages of hollow-fiber membrane oxygenators, eliminated plasma leakage and extended maximum duration. Compared to roller pumps, magnetically levitated centrifugal pumps had better performance in the protection of blood elements and reduction of coagulation system activation. Moreover, advances in circuits allowed for smaller surface area, less priming, easier management, and longer duration. Fewer pediatric formulations of anticoagulation agents, lack of widespread experience, and limited expertise challenged anticoagulation and hemostasis in children. Comparisons should be made to determine the optimal combination of coagulation monitoring parameters to achieve goal-directed anticoagulation management and better clinical outcomes.\[[@ref21]\] In this study, we detected significant decreases in neurological and renal complications over time. A previous study reported that central nervous system (CNS) injury could occur in 22% of ECPR patients.\[[@ref22]\] Some new therapies, such as active compression/decompression CPR with intrathoracic pressure regulation, heads-up CPR, sodium nitroprusside-enhanced CPR, and postconditioning strategies, have shown promising improvements in animal models as well as in early stages of human trials. Bundling them together could have the potential to bring better neurological survival after cardiac arrest.\[[@ref23]\] The insufficiency of renal function might suggest worse outcomes for children receiving ECPR. A retrospective observational study performed by Smith *et al*.\[[@ref24]\] showed that acute renal failure was associated with a significant increase in mortality. Various methods of dialysis, especially peritoneal dialysis, achieved varying degrees of success in ECMO patients.\[[@ref25][@ref26]\] Moreover, continuous venovenous hemofiltration could be beneficial to those patients for its tight control of fluid balance and decreased diuretic requirements, as reported by Wolf *et al*.\[[@ref27]\] The decrease in the incidence of renal complications in this study might also be related to enhance circulatory support level and decreased use of vasoactive drugs. High blood glucose has been associated with decreased survival and poor neurological outcomes.\[[@ref28][@ref29]\] The improvements in hyperglycemia control during ECPR might improve CNS protection and in-hospital survival, though further study is necessary.

Comparisons were also performed between survivors and nonsurvivors. Asian patients accounted for 42.7% of subjects in this study and showed worse survival compared to other race categorizations. Mosca *et al*.\[[@ref30]\] found that the Hispanic population had reduced survival in venovenous ECMO. Survival differences between racial subgroups and their possible factors are a worthy topic for further studies. Children with congenital heart disease were more likely to survive in this study and in Chan *et al*.\'s report.\[[@ref31]\] One possible explanation for this finding was that ECMO was often performed as a transitional method before and after operations, providing a chance of recovery for children. Anesthetic and neuromuscular blockers were more commonly used in the surviving group, which could be related to their more extensive use in children with congenital heart disease as transitional means before operations and their potential protection of the CNS and reduction of stress reactions.\[[@ref23]\] In multiple logistic regression analysis, several factors were identified as independent risk factors of in-hospital mortality. Myocardial stunning confirmed by ultrasonography was a strong risk factor in this study (odds ratio: 10.23, 95% confidence interval: 1.20--87.41), in keeping with a previous study by Usui *et al*.\[[@ref32]\]

To our knowledge, this study is the largest and, in fact, the only investigation of ECPR in children in Asia Pacific. There some limitations in this study, which are as follows: (1) it was a retrospective study and the data included were uncontrolled; (2) there has been a sustained increase in active centers in ELSO, and not all ECPR cases in Asia Pacific were included in the registry; (3) only ECPR patients were analyzed, and this study could not assess the role of ECMO during CPR; and (4) it is unknown if the progress of technology and changes in anticoagulation strategy are directly related to the marked decline in mechanical and hemorrhagic complications. Further studies on related topics are required to benefit more patients.

In conclusion, the broader indications and decreased complication rates make EPCR to be applicated more and more extensive in children in Asia Pacific region. ECMO complications such as myocardial stunning are independently associated with decreased survival.
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